{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:26:50Z","timestamp":1794558410536,"version":"4.9.1"},"reference-count":271,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"publisher","award":["SVV 260 764"],"award-info":[{"award-number":["SVV 260 764"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","award":["MH CZ-DRO VFN64165"],"award-info":[{"award-number":["MH CZ-DRO VFN64165"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","award":["NU23-04-00032"],"award-info":[{"award-number":["NU23-04-00032"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.pnpbp.2026.111749","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:47:38Z","timestamp":1779230858000},"page":"111749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Advances in schizophrenia research and treatment: exploring neurotransmitter imbalances, genetics, and innovative therapies"],"prefix":"10.1016","volume":"147","author":[{"given":"Karol\u00edna","family":"\u0160kutov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zden\u011bk","family":"Fi\u0161ar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Hroudov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2026.111749_bb0015","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2402732121","article-title":"Ketamine can produce oscillatory dynamics by engaging mechanisms dependent on the kinetics of NMDA receptors","volume":"121","author":"Adam","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0020","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0165-0173(99)00046-6","article-title":"Serotonin model of schizophrenia: emerging role of glutamate mechanisms","volume":"31","author":"Aghajanian","year":"2000","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0025","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.psyneuen.2012.05.003","article-title":"Stress abnormalities in individuals at risk for psychosis: a review of studies in subjects with familial risk or with \u201cat risk\u201d mental state","volume":"37","author":"Aiello","year":"2012","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0035","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1038\/s41380-024-02503-x","article-title":"Advancing understanding of the mechanisms of antipsychotic-associated cognitive impairment to minimise harm: a call to action","volume":"29","author":"Allott","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/acps.12440","article-title":"Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder","volume":"133","author":"Amann","year":"2016","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0045","doi-asserted-by":"crossref","first-page":"pyae061","DOI":"10.1093\/ijnp\/pyae061","article-title":"Therapeutic effect of evenamide, a glutamate inhibitor, in patients with treatment-resistant schizophrenia (TRS): final, 1-year results from a phase 2, open-label, rater-blinded, randomized, international clinical trial","volume":"28","author":"Anand","year":"2024","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.110275","volume":"266","author":"Anand","year":"2025","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0055","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pnpbp.2012.06.014","article-title":"Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression","volume":"42","author":"Anderson","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0060","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/schbul\/sbu009","article-title":"Hippocampal volume is reduced in schizophrenia and schizoaffective disorder but not in psychotic bipolar I disorder demonstrated by both manual tracing and automated parcellation (FreeSurfer)","volume":"41","author":"Arnold","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0065","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mp.2017.16","article-title":"The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment","volume":"22","author":"Ashok","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0070","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.semcdb.2017.10.016","article-title":"Gene-environment interaction and psychiatric disorders: Review and future directions","volume":"77","author":"Assary","year":"2018","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0075","doi-asserted-by":"crossref","first-page":"12258","DOI":"10.1038\/s41598-020-69207-4","article-title":"Mitochondrial function parameters as a tool for tailored drug treatment of an individual with psychosis: a proof of concept study","volume":"10","author":"Bar-Yosef","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107690","article-title":"IUPHAR review - novel therapeutic targets for schizophrenia treatment: a translational perspective","volume":"214","author":"Begni","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0085","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/acps.12847","article-title":"Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses","volume":"137","author":"Belbasis","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0090","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1177\/0271678X241238820","article-title":"PET imaging of M4 muscarinic acetylcholine receptors in rhesus macaques using [11C]MK-6884: Quantification with kinetic modeling and receptor occupancy by CVL-231 (emraclidine), a novel positive allosteric modulator","volume":"44","author":"Belov","year":"2024","journal-title":"J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.schres.2016.10.022","article-title":"Mitochondrial multifaceted dysfunction in schizophrenia; complex I as a possible pathological target","volume":"187","author":"Ben-Shachar","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0100","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/0706743716648290","article-title":"Mitochondrial oxidative phosphorylation system (OXPHOS) deficits in schizophrenia: possible interactions with cellular processes","volume":"61","author":"Bergman","year":"2016","journal-title":"Can. J. Psychiatry Rev. Can. Psychiatr."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0105","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/ijnp\/pyx074","article-title":"Tolcapone-enhanced neurocognition in healthy adults: neural basis and predictors","volume":"20","author":"Bhakta","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0110","doi-asserted-by":"crossref","first-page":"15239","DOI":"10.1038\/s41598-024-65566-4","article-title":"Loss of dysbindin-1 in excitatory neurons in mice impacts NMDAR-dependent behaviors, neuronal morphology and synaptic transmission in the ventral hippocampus","volume":"14","author":"Bhardwaj","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0115","series-title":"Laxminarayan Bhat (Presenter, Pictured)","author":"Bhat","year":"2024"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0125","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2217\/pgs.10.206","article-title":"Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia","volume":"12","author":"Bitsios","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pnpbp.2026.111749_bib1441","author":"Boehringer Ingelheim"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0135","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1134\/S1819712423040086","article-title":"Anomalies of energy metabolism in schizophrenia and possible pathogenetically targeted therapeutic approaches","volume":"17","author":"Boksha","year":"2023","journal-title":"Neurochem. J."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0140","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/brainsci14111089","article-title":"Dopaminergic epistases in schizophrenia","volume":"14","author":"Bosun","year":"2024","journal-title":"Brain Sci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0145","doi-asserted-by":"crossref","first-page":"eaap8757","DOI":"10.1126\/science.aap8757","article-title":"Analysis of shared heritability in common disorders of the brain","volume":"360","author":"Brainstorm Consortium","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0155","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3390\/biomedicines11030921","article-title":"Efficacy of serotonin and dopamine activity modulators in the treatment of negative symptoms in schizophrenia: a rapid review","volume":"11","author":"Brasso","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0160","article-title":"The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue","volume":"5","author":"Brisch","year":"2014","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pneurobio.2010.09.003","article-title":"The environment and susceptibility to schizophrenia","volume":"93","author":"Brown","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0170","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2019.07.008","article-title":"Heterogeneity of striatal dopamine function in schizophrenia: meta-analysis of variance","volume":"87","author":"Brugger","year":"2020","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0175","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3390\/biom10030384","article-title":"Oxidative-antioxidant imbalance and impaired glucose metabolism in schizophrenia","volume":"10","author":"Bryll","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0180","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.euroneuro.2010.10.007","article-title":"Abnormalities in the tricarboxylic acid (TCA) cycle in the brains of schizophrenia patients","volume":"21","author":"Bubber","year":"2011","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0185","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2215-0366(21)00386-2","article-title":"Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe","volume":"9","author":"Bugarski-Kirola","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0190","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1017\/S0033291719001995","article-title":"An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis","volume":"49","author":"\u00c7akici","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0195","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/schbul\/sbu016","article-title":"Genetic relationships between schizophrenia, bipolar disorder, and schizoaffective disorder","volume":"40","author":"Cardno","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0200","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0893-133X(88)90012-7","article-title":"The current status of the dopamine hypothesis of schizophrenia","volume":"1","author":"Carlsson","year":"1988","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0205","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.3390\/nu16244404","article-title":"The gut microbiota\u2019s role in neurological, psychiatric, and neurodevelopmental disorders","volume":"16","author":"Charitos","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0210","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41398-020-01095-8","article-title":"A randomised clinical trial of methotrexate points to possible efficacy and adaptive immune dysfunction in psychosis","volume":"10","author":"Chaudhry","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1356975","article-title":"Neuroinflammation and schizophrenia \u2013 is there a link?","volume":"15","author":"Chaves","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0220","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2147\/NDT.S373492","article-title":"CACNA1C Gene rs1006737 polymorphism affects cognitive performance in chinese han schizophrenia","volume":"18","author":"Chen","year":"2022","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0225","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/schbul\/sbae044","article-title":"Shared genetic determinants of schizophrenia and autism spectrum disorder implicate opposite risk patterns: a genome-wide analysis of common variants","volume":"50","author":"Chen","year":"2024","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0230","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/0004867419835028","article-title":"Adjunctive use of anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials","volume":"53","author":"Cho","year":"2019","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.585742","article-title":"Maternal immune activation and schizophrenia\u2013evidence for an immune priming disorder","volume":"12","author":"Choudhury","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0240","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00210-019-01665-8","article-title":"In vitro effects of antipsychotics on mitochondrial respiration","volume":"392","author":"Cik\u00e1nkov\u00e1","year":"2019","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000604","article-title":"Increased expression of schizophrenia-associated gene C4 leads to hypoconnectivity of prefrontal cortex and reduced social interaction","volume":"18","author":"Comer","year":"2020","journal-title":"PLOS Biol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0250","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamapsychiatry.2019.4379","article-title":"Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial","volume":"77","author":"Correll","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0255","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41537-022-00320-1","article-title":"Safety and tolerability of KarXT (xanomeline\u2013trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia","volume":"8","author":"Correll","year":"2022","journal-title":"Schizophrenia"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0260","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3390\/biom14080906","article-title":"What remains to be discovered in schizophrenia therapeutics: contributions by advancing the molecular mechanisms of drugs for psychosis and schizophrenia","volume":"14","author":"Correll","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0265","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0270","series-title":"Mental Health","author":"Dattani","year":"2023"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0275","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/schbul\/sbac013","article-title":"Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia","volume":"48","author":"Davidson","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.00369","article-title":"Glycine signaling in the framework of dopamine-glutamate interaction and postsynaptic density. Implications for treatment-resistant schizophrenia","volume":"11","author":"de Bartolomeis","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0290","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.schres.2014.10.055","article-title":"Innate immune response is differentially dysregulated between bipolar disease and schizophrenia","volume":"161","author":"de Baumont","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0295","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3390\/antiox12040975","article-title":"Schizophrenia synaptic pathology and antipsychotic treatment in the framework of oxidative and mitochondrial dysfunction: translational highlights for the clinics and treatment","volume":"12","author":"De Simone","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.112989","article-title":"Muscarinic M1 and M4 receptors: hypothesis driven drug development for schizophrenia","volume":"288","author":"Dean","year":"2020","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0305","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2015.10.028","article-title":"Changes in cholinergic and glutamatergic markers in the striatum from a sub-set of subjects with schizophrenia","volume":"169","author":"Dean","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0310","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.226","article-title":"Evidence for impaired glucose metabolism in the striatum, obtained postmortem, from some subjects with schizophrenia","volume":"6","author":"Dean","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0315","doi-asserted-by":"crossref","first-page":"13185","DOI":"10.3390\/ijms222413185","article-title":"Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies","volume":"22","author":"Dedic","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0320","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/ph18030324","article-title":"Available treatments for autism spectrum disorder: from old strategies to new options","volume":"18","author":"Dell\u2019Osso","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0325","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3390\/genes15030272","article-title":"Epigenetic regulation in schizophrenia: focus on methylation and histone modifications in human studies","volume":"15","author":"Delphin","year":"2024","journal-title":"Genes"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0330","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11739-023-03374-w","article-title":"Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review","volume":"19","author":"Di Vincenzo","year":"2024","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0335","author":"Dickerson"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0340","article-title":"Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial","volume":"16","author":"Dickerson","year":"2014","journal-title":"Prim. Care Companion CNS Disord."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0345","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neubiorev.2020.09.028","article-title":"Trace Amine-Associated Receptor 1 (TAAR1): A new drug target for psychiatry?","volume":"120","author":"Dodd","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0350","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.biopsych.2007.07.022","article-title":"Early visual processing deficits in dysbindin-associated schizophrenia","volume":"63","author":"Donohoe","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0355","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/schbul\/sbq080","article-title":"The psychosis susceptibility gene ZNF804A: associations, functions, and phenotypes","volume":"36","author":"Donohoe","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0360","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/jamapsychiatry.2013.2287","article-title":"In vivo evidence for cerebral bioenergetic abnormalities in schizophrenia measured using 31P magnetization transfer spectroscopy","volume":"71","author":"Du","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0365","article-title":"Shared genetic networks in schizophrenia and bipolar disorder: hippocampal volume-mediated neurobiological mechanisms","volume":"sbaf092","author":"Du","year":"2025","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0370","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0920-9964(03)00220-2","article-title":"The 3\u2019 region of the DRD2 gene is involved in genetic susceptibility to schizophrenia","volume":"67","author":"Dubertret","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-024-00440-w","article-title":"Association study of the complement component C4 gene and suicide risk in schizophrenia","volume":"10","author":"Ebrahimi","year":"2024","journal-title":"Schizophrenia"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0385","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.schres.2020.09.013","article-title":"Glutamate in schizophrenia: neurodevelopmental perspectives and drug development","volume":"223","author":"Egerton","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0390","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.mehy.2013.03.013","article-title":"A serotonin hypothesis of schizophrenia","volume":"80","author":"Eggers","year":"2013","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0395","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s43045-025-00585-z","article-title":"The gut\u2013brain axis in depression, anxiety, and schizophrenia: a scoping review of mechanisms, biomarkers, and therapeutic implications","volume":"32","author":"Eskandar","year":"2025","journal-title":"Middle East Curr. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0400","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.3390\/ijms26094331","article-title":"Glutamate-based therapeutic strategies for schizophrenia: emerging approaches beyond dopamine","volume":"26","author":"Fadgyas-Stanculete","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0405","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1126\/science.128.3320.358","article-title":"On the relationship of serotonin to schizophrenia","volume":"128","author":"Feldstein","year":"1958","journal-title":"Science"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2022.110626","article-title":"Biological hypotheses, risk factors, and biomarkers of schizophrenia","volume":"120","author":"Fi\u0161ar","year":"2023","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0415","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.toxlet.2020.12.012","article-title":"Effects of novel 17\u03b2-hydroxysteroid dehydrogenase type 10 inhibitors on mitochondrial respiration","volume":"339","author":"Fi\u0161ar","year":"2021","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0420","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.3390\/ijms24097991","article-title":"Mitochondrial dysfunction, altered mitochondrial oxygen, and energy metabolism associated with the pathogenesis of schizophrenia","volume":"24","author":"Fiz\u00edkov\u00e1","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0425","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.biopsych.2013.03.018","article-title":"Meta-analysis of oxidative stress in schizophrenia","volume":"74","author":"Flatow","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0430","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2215-0366(20)30513-7","article-title":"Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study","volume":"8","author":"Fleischhacker","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.00160","article-title":"The role of inflammation in the treatment of schizophrenia","volume":"11","author":"Fond","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0440","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/s41380-024-02531-7","article-title":"Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor","volume":"29","author":"Gaitonde","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0445","article-title":"Gut-brain axis and neurodegeneration: mechanisms and therapeutic potentials","volume":"18","author":"Gao","year":"2024","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0450","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.640463","article-title":"A review on the expression pattern of non-coding RNAs in patients with schizophrenia: with a special focus on peripheral blood as a source of expression analysis","volume":"12","author":"Ghafouri-Fard","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0455","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0298161","article-title":"Metabolic Syndrome in people treated with Antipsychotics (RISKMet): A multimethod study protocol investigating genetic, behavioural, and environmental risk factors","volume":"19","author":"Girolamo","year":"2024","journal-title":"PLOS ONE"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0460","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.npp.1301444","article-title":"A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia","volume":"33","author":"Goff","year":"2008","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0465","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/mp.2016.3","article-title":"A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression","volume":"21","author":"Goldsmith","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0470","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.3390\/ijms22094467","article-title":"Beyond dopamine receptor antagonism: new targets for schizophrenia treatment and prevention","volume":"22","author":"Gomes","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0475","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1002\/hbm.22560","article-title":"A brain-wide association study of DISC1 genetic variants reveals a relationship with the structure and functional connectivity of the precuneus in schizophrenia","volume":"35","author":"Gong","year":"2014","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0480","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/emmm.201100135","article-title":"A CAG repeat polymorphism of KCNN3 predicts SK3 channel function and cognitive performance in schizophrenia","volume":"3","author":"Grube","year":"2011","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0485","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2016.00089","article-title":"Epigenetic RELN dysfunction in schizophrenia and related neuropsychiatric disorders","volume":"10","author":"Guidotti","year":"2016","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0490","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/JCP.0b013e31819302c3","article-title":"Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine","volume":"29","author":"Gunes","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0495","article-title":"Network-based drug repurposing for psychiatric disorders using single-cell genomics","author":"Gupta","year":"2024","journal-title":"MedRxiv Prepr. Serv. Health Sci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0500","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/PROM.S42735","article-title":"Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies","volume":"5","author":"Haddad","year":"2014","journal-title":"Patient Relat. Outcome Meas."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0505","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2024.1345349","article-title":"Microglia-neuron interactions in schizophrenia","volume":"18","author":"Hartmann","year":"2024","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0510","article-title":"Efficacy and safety of iclepertin (BI 425809) with adjunctive computerized cognitive training in patients with schizophrenia","volume":"40","author":"Harvey","year":"2025","journal-title":"Schizophr. Res. Cogn."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2025.110351","article-title":"Synergistic insights into positive allosteric modulator and agonist using Gaussian accelerated and tau random acceleration simulations in the metabotropic glutamate receptor 2","volume":"269","author":"He","year":"2025","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0520","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2016.15081035","article-title":"Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis","author":"Helfer","year":"2016","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0525","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/s41380-022-01494-x","article-title":"Schizophrenia: a disorder of broken brain bioenergetics","volume":"27","author":"Henkel","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0530","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archpsyc.56.1.29","article-title":"Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia","volume":"56","author":"Heresco-Levy","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0535","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.682611","article-title":"From the clinic to the laboratory, and back again: investigations on cannabinoids and endocannabinoid system modulators for treating schizophrenia","volume":"12","author":"Hoffman","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0540","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0269881105058379","article-title":"Diabetes and schizophrenia 2005: are we any closer to understanding the link?","volume":"19","author":"Holt","year":"2005","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0550","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.biopsych.2022.06.017","article-title":"Integrating the neurodevelopmental and dopamine hypotheses of schizophrenia and the role of cortical excitation-inhibition balance","volume":"92","author":"Howes","year":"2022","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0555","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.biopsych.2016.07.014","article-title":"The role of genes, stress, and dopamine in the development of schizophrenia","volume":"81","author":"Howes","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0560","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.biopsych.2024.05.014","article-title":"New drug treatments for schizophrenia: a review of approaches to target circuit dysfunction","volume":"96","author":"Howes","year":"2024","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0565","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jpsychires.2025.11.029","article-title":"Integrated metagenome and metabolome analysis reveals a disease signature of gut microbiota and the key gut microbiota-associated metabolite proline in schizophrenia","volume":"193","author":"Huang","year":"2025","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0570","doi-asserted-by":"crossref","first-page":"12390","DOI":"10.1523\/JNEUROSCI.1689-07.2007","article-title":"Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization","volume":"27","author":"Iizuka","year":"2007","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2013.00076","article-title":"Major channels involved in neuropsychiatric disorders and therapeutic perspectives","volume":"4","author":"Imbrici","year":"2013","journal-title":"Front. Genet."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0580","doi-asserted-by":"crossref","DOI":"10.5498\/wjp.v15.i5.103751","article-title":"Gut-brain connection in schizophrenia: a narrative review","volume":"15","author":"Iqbal","year":"2025","journal-title":"World J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0585","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.biopsych.2006.03.065","article-title":"A review of Disrupted-In-Schizophrenia-1 (DISC1): neurodevelopment, cognition, and mental conditions","volume":"59","author":"Ishizuka","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0590","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.euroneuro.2024.07.005","article-title":"Network intervention analysis indicates that roluperidone achieves its effect on negative symptoms of schizophrenia by targeting avolition","volume":"87","author":"James","year":"2024","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0595","doi-asserted-by":"crossref","first-page":"27654","DOI":"10.1038\/s41598-024-78220-w","article-title":"Expression pattern of long non-coding RNAs in treatment-na\u00efve and medicated schizophrenia patients","volume":"14","author":"Javidi Aghdam","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0600","author":"Jim\u00e9nez"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0605","doi-asserted-by":"crossref","first-page":"1451248","DOI":"10.3389\/fpsyt.2024.1451248","article-title":"Serotonin and schizophrenia: what influences what?","volume":"15","author":"Jim\u00e9nez-Trejo","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0610","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1007\/s00787-023-02333-2","article-title":"Shared atypical spontaneous brain activity pattern in early onset schizophrenia and autism spectrum disorders: evidence from cortical surface-based analysis","volume":"33","author":"Jin","year":"2024","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0615","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/schbul\/sbq135","article-title":"DISC1 in schizophrenia: genetic mouse models and human genomic imaging","volume":"37","author":"Johnstone","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0620","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pneurobio.2014.02.003","article-title":"Serotonin transporter polymorphisms (5-HTTLPR) in emotion processing: implications from current neurobiology","volume":"117","author":"Jonassen","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0625","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/schbul\/sbx021.164","article-title":"116.2 discovery and development of novel M1 and M4 PAMs for the treatment of schizophrenia","volume":"43","author":"Jones","year":"2017","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0630","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.3390\/nu15204391","article-title":"The gut\u2013brain axis in schizophrenia: the implications of the gut microbiome and SCFA production","volume":"15","author":"Ju","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0635","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.schres.2021.04.009","article-title":"A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension","volume":"232","author":"Kahn","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0640","series-title":"Milsaperidone Under Review for Bipolar I Disorder and Schizophrenia","author":"Kang","year":"2025"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0645","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/ijnp\/pyad011","article-title":"New developments in the treatment of schizophrenia: an expert roundtable","volume":"26","author":"Kantrowitz","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0650","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.schres.2019.03.003","article-title":"Pro-cognitive effect of a prebiotic in psychosis: a double blind placebo controlled cross-over study","volume":"208","author":"Kao","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0665","author":"Karuna Therapeutics"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0670","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111749_bb0150","doi-asserted-by":"crossref","first-page":"24m15497","DOI":"10.4088\/JCP.24m15497","article-title":"Safety and tolerability of xanomeline and trospium chloride in schizophrenia: Pooled results from the 5-week, randomized, double-blind, placebo-controlled EMERGENT trials","volume":"86","author":"Kaul","year":"2025","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0675","article-title":"5-HT1A and 5-HT2A signaling, desensitization, and downregulation: serotonergic dysfunction and abnormal receptor density in schizophrenia and the prodrome","volume":"13","author":"Kim","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0680","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1017\/S1092852924000130","article-title":"A systematic review of the cognitive effects of the COMT inhibitor, tolcapone, in adult humans","volume":"29","author":"Kings","year":"2024","journal-title":"CNS Spectr."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111749_bb0685","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/d41573-022-00010-8","article-title":"Structural improvements to antipsychotics","volume":"21","author":"Kingwell","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0690","doi-asserted-by":"crossref","first-page":"23nr15240","DOI":"10.4088\/JCP.23nr15240","article-title":"Rationale for adjunctive treatment targeting multiple mechanisms in schizophrenia","volume":"85","author":"Kinon","year":"2024","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0695","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/S0140-6736(22)01990-0","article-title":"Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial","volume":"400","author":"Krystal","year":"2022","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0700","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021635","article-title":"MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia","volume":"6","author":"Lai","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0705","doi-asserted-by":"crossref","first-page":"506","DOI":"10.2174\/156652409788167104","article-title":"The role of genes involved in neuroplasticity and neurogenesis in the observation of a gene-environment interaction (GxE) in schizophrenia","volume":"9","author":"Le Strat","year":"2009","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0710","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jad.2020.04.056","article-title":"Prevalence of comorbid depression in schizophrenia: a meta-analysis of observational studies","volume":"273","author":"Li","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0715","article-title":"Alterations of the gut microbiota in patients with schizophrenia","volume":"15","author":"Li","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0720","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.3390\/ijms25147673","article-title":"The role of microrna in schizophrenia: a scoping review","volume":"25","author":"Li","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0725","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3390\/foods14101773","article-title":"Effect of supplementation with probiotics in patients with schizophrenia: systematic review and meta-analysis of randomized controlled clinical trials","volume":"14","author":"Li","year":"2025","journal-title":"Foods"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0735","first-page":"38","article-title":"A cannabinoid hypothesis of schizophrenia: pathways to psychosis","volume":"19","author":"Little","year":"2022","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0740","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10571-020-00792-8","article-title":"TAAR1 and psychostimulant addiction","volume":"40","author":"Liu","year":"2020","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0745","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.scog.2015.10.002","article-title":"The impact of the Val158Met COMT polymorphism on context processing in patients on the schizophrenia spectrum and their relatives","volume":"2","author":"L\u00f3pez-Garc\u00eda","year":"2015","journal-title":"Schizophr. Res. Cogn."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0755","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1007\/s12035-021-02498-4","article-title":"Effect of novel antipsychotics on energy metabolism - in vitro study in pig brain mitochondria","volume":"58","author":"\u013dupt\u00e1k","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0760","author":"Lutton"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0765","series-title":"Novel and Emerging Pharmacologic Treatments for Schizophrenia","author":"Lykke","year":"2023"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2024.103578","article-title":"Alterations in type 2 dopamine receptors across neuropsychiatric conditions: a large-scale PET cohort","volume":"41","author":"Mal\u00e9n","year":"2024","journal-title":"NeuroImage Clin."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0775","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/gbb.12355","article-title":"The impact of CACNA1C gene, and its epistasis with ZNF804A, on white matter microstructure in health, schizophrenia and bipolar disorder1","volume":"16","author":"Mallas","year":"2017","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0780","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.3390\/nu15061496","article-title":"The microbiota\u2013gut\u2013brain axis: psychoneuroimmunological insights","volume":"15","author":"Marano","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0785","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0920-9964(03)00011-2","article-title":"A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress","volume":"65","author":"Marchbanks","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0790","doi-asserted-by":"crossref","first-page":"282","DOI":"10.9740\/mhc.2022.10.282","article-title":"Management of cognitive and negative symptoms in schizophrenia","volume":"12","author":"Maroney","year":"2022","journal-title":"Ment. Health Clin."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0795","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1007\/s00213-021-05900-0","article-title":"Adenosine A2A receptor in schizophrenia: an in vivo brain PET imaging study","volume":"239","author":"Marques","year":"2022","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0800","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/schbul\/sbr069","article-title":"Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies","volume":"39","author":"Marsman","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0805","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.neulet.2004.12.059","article-title":"5-HT2A and muscarinic receptors in schizophrenia: a postmortem study","volume":"379","author":"Matsumoto","year":"2005","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0810","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0920-9964(00)00075-X","article-title":"Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia","volume":"48","author":"Maurer","year":"2001","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0820","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.schres.2018.10.009","article-title":"Neuropsychological functioning in early and chronic stages of schizophrenia and psychotic bipolar disorder","volume":"206","author":"Menkes","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0825","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1017\/S1092852922000967","article-title":"Olanzapine\/samidorphan combination consistently mitigates weight gain across various subgroups of patients","volume":"28","author":"Meyer","year":"2023","journal-title":"CNS Spectr."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0830","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1523\/JNEUROSCI.22-07-02718.2002","article-title":"Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia","volume":"22","author":"Middleton","year":"2002","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0835","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3390\/brainsci11101298","article-title":"HPA Axis in the pathomechanism of depression and schizophrenia: new therapeutic strategies based on its participation","volume":"11","author":"Mikulska","year":"2021","journal-title":"Brain Sci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0840","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0855","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0860","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/brain\/awab096","article-title":"Dissecting autism and schizophrenia through neuroimaging genomics","volume":"144","author":"Moreau","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0865","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.3390\/ijms26094415","article-title":"Mitochondrial oxidative phosphorylation system dysfunction in schizophrenia","volume":"26","author":"Mor\u00e9n","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0870","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1007\/s11033-020-05590-5","article-title":"The interplay between oxidative stress and bioenergetic failure in neuropsychiatric illnesses: can we explain it and can we treat it?","volume":"47","author":"Morris","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105729","article-title":"The endocannabinoidome in neuropsychiatry: opportunities and potential risks","volume":"170","author":"Morris","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0880","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1007\/s12035-022-02800-y","article-title":"Inflammation and nitro-oxidative stress as drivers of endocannabinoid system aberrations in mood disorders and schizophrenia","volume":"59","author":"Morris","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0885","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3390\/life15030391","article-title":"Third-generation antipsychotics: the quest for the key to neurotrophism","volume":"15","author":"Mucci","year":"2025","journal-title":"Life"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0890","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/schbul\/sby024","article-title":"Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations","volume":"44","author":"M\u00fcller","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0895","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1586\/14737175.8.7.1037","article-title":"Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia","volume":"8","author":"M\u00fcller-Vahl","year":"2008","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0900","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.schres.2024.06.017","article-title":"INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia","volume":"270","author":"Murthy","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0905","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1021\/acsptsci.2c00016","article-title":"Trace amine-associated receptor 1 (TAAR1): molecular and clinical insights for the treatment of schizophrenia and related comorbidities","volume":"5","author":"Nair","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0910","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0893-133X(98)00067-0","article-title":"Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis","volume":"20","author":"Newcomer","year":"1999","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0915","doi-asserted-by":"crossref","first-page":"17349","DOI":"10.1038\/srep17349","article-title":"CACNA1C risk variant affects facial emotion recognition in healthy individuals","volume":"5","author":"Nieratschker","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0920","article-title":"Stress and the gut-brain axis: an inflammatory perspective","volume":"17","author":"Nowacka-Chmielewska","year":"2024","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0925","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/ng.201","article-title":"Identification of loci associated with schizophrenia by genome-wide association and follow-up","volume":"40","author":"O\u2019Donovan","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0930","doi-asserted-by":"crossref","first-page":"14478","DOI":"10.1021\/acs.jmedchem.4c01244","article-title":"Dual 5-HT2A and 5-HT2C receptor inverse agonist that affords in vivo antipsychotic efficacy with minimal hERG inhibition for the treatment of dementia-related psychosis","volume":"67","author":"Oguma","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0935","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1111\/bph.70112","article-title":"Exploring the pathophysiology underlying clozapine-induced enhancement of glutamatergic transmission through L-glutamate and D-serine release associated with pannexin1 hemichannels","volume":"182","author":"Okada","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0940","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jad.2018.11.011","article-title":"Effect of bifidobacterium breve A-1 on anxiety and depressive symptoms in schizophrenia: A proof-of-concept study","volume":"245","author":"Okubo","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0945","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3390\/biom14091128","article-title":"Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and\/or the Pathomechanisms of Treatment-Resistant Schizophrenia","volume":"14","author":"Okubo","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0950","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1038\/s41380-023-02293-8","article-title":"Genomic findings in schizophrenia and their implications","volume":"28","author":"Owen","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0955","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00406-023-01727-2","article-title":"Effects of antipsychotic drugs on energy metabolism","volume":"274","author":"Panizzutti","year":"2024","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0960","article-title":"Lumateperone: advancing schizophrenia treatment with a new antipsychotic","author":"Pardossi","year":"2024","journal-title":"Ital. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0965","doi-asserted-by":"crossref","DOI":"10.3389\/fnsyn.2025.1656232","article-title":"Is it possible to prevent excessive synaptic pruning in schizophrenia? possibilities and limitations","volume":"17","author":"Pawlak","year":"2025","journal-title":"Front. Synaptic Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0970","doi-asserted-by":"crossref","first-page":"pyae052","DOI":"10.1093\/ijnp\/pyae052","article-title":"Efficacy and safety of lumateperone for bipolar depression and schizophrenia: a systematic review and meta-analysis","volume":"27","author":"Peng","year":"2024","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109514","article-title":"Functional crosstalk of the glycine transporter GlyT1 and NMDA receptors","volume":"232","author":"Piniella","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0980","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3390\/life11100997","article-title":"Study of early onset schizophrenia: associations of GRIN2A and GRIN2B polymorphisms","volume":"11","author":"Poltavskaya","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0985","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.1192\/j.eurpsy.2023.763","article-title":"Association of rs11644461 GRIN2A with clinical phenotype of schizophrenia","volume":"66(Suppl 1)","author":"Poltavskaya","year":"2023","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb0990","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3390\/genes14030575","article-title":"The role of glutamatergic gene polymorphisms in the clinical phenotypes of schizophrenia","volume":"14","author":"Poltavskaya","year":"2023","journal-title":"Genes"},{"issue":"684\u2013697","key":"10.1016\/j.pnpbp.2026.111749_bb0995","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.mp.4001532","article-title":"Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress","volume":"9","author":"Prabakaran","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1000","series-title":"Long-Term Effects of Roluperidone on Negative Symptoms of Schizophrenia","author":"Rabinowitz","year":"2022"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jpsychires.2025.04.019","article-title":"Antipsychotic-like pharmacological profile of the low impact ampakine CX691 (farampator): implications for the use of low impact ampakines in the treatment of schizophrenia","volume":"186","author":"Radin","year":"2025","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1010","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.160.1.118","article-title":"In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia","volume":"160","author":"Raedler","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1015","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3390\/antiox13060709","article-title":"The underlying neurobiological mechanisms of psychosis: focus on neurotransmission dysregulation, neuroinflammation, oxidative stress, and mitochondrial dysfunction","volume":"13","author":"Rawani","year":"2024","journal-title":"Antioxidants"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1025","article-title":"Executive dysfunction in MCI: subtype or early symptom","volume":"2012","author":"Reinvang","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1030","author":"Reviva Pharmaceuticals"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2020.03.008","article-title":"Epigenetic modifications in schizophrenia and related disorders: molecular scars of environmental exposures and source of phenotypic variability","volume":"89","author":"Richetto","year":"2021","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.mito.2020.11.009","article-title":"Mitochondrial dysfunction in schizophrenia: with a focus on postmortem studies","volume":"56","author":"Roberts","year":"2021","journal-title":"Mitochondrion"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1045","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/s41380-024-02740-0","article-title":"Uncovering convergence and divergence between autism and schizophrenia using genomic tools and patients\u2019 neurons","volume":"30","author":"Romanovsky","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1050","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jpsychires.2025.01.050","article-title":"Impact of probiotic treatment on clinical symptom reduction in schizophrenia: a systematic review and meta-analysis","volume":"182","author":"Romero-Ferreiro","year":"2025","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1055","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s00406-023-01576-z","article-title":"Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia","volume":"273","author":"Rosenbrock","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1060","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10571-018-0640-3","article-title":"Expression pattern of long non-coding RNAs in schizophrenic patients","volume":"39","author":"Safari","year":"2019","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1065","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/cells13010032","article-title":"Adenosine receptor mRNA expression in frontal cortical neurons in schizophrenia","volume":"13","author":"Sahay","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1070","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.3390\/cells13191657","article-title":"Adenosine metabolism pathway alterations in frontal cortical neurons in schizophrenia","volume":"13","author":"Sahay","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1075","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-025-03023-y","article-title":"Cholinergic system in schizophrenia: a systematic review and meta-analysis","author":"Saint-Georges","year":"2025","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1080","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.947563","article-title":"Glycine neurotransmission: its role in development","volume":"16","author":"Salceda","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1085","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2024.09.029","article-title":"Association of CACNA1C polymorphisms (rs1006737, rs4765905, rs2007044) with schizophrenia: a meta-analysis and trial sequential analysis","volume":"274","author":"Sarangi","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1090","series-title":"Bristol Myers Wins US FDA Approval for New Type of Schizophrenia Drug","author":"Satija","year":"2024"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1095","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1471-4159.2008.05711.x","article-title":"Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?","volume":"107","author":"Scarr","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1100","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/mp.2016.195","article-title":"Changed gene expression in subjects with schizophrenia and low cortical muscarinic M1 receptors predicts disrupted upstream pathways interacting with that receptor","volume":"23","author":"Scarr","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1105","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics Consortium","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1110","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1038\/s41467-023-39420-6","article-title":"Schizophrenia-associated NRXN1 deletions induce developmental-timing- and cell-type-specific vulnerabilities in human brain organoids","volume":"14","author":"Sebastian","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1115","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.biopsych.2024.08.019","article-title":"Finding the right dose: NMDA receptor-modulating treatments for cognitive and plasticity deficits in schizophrenia and the role of pharmacodynamic target engagement","volume":"97","author":"Sehatpour","year":"2025","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.136064","article-title":"The endocannabinoid system as a therapeutic target for schizophrenia: Failures and potentials","volume":"759","author":"Seillier","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1125","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature16549","article-title":"Schizophrenia risk from complex variation of complement component 4","volume":"530","author":"Sekar","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127280","article-title":"Mitochondrial mutations in subjects with psychiatric disorders","volume":"10","author":"Sequeira","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1601-183X.2007.00323.x","article-title":"Novel alpha7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia","volume":"7","author":"Severance","year":"2008","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bbi.2016.11.019","article-title":"Probiotic normalization of Candida albicans in schizophrenia: a randomized, placebo-controlled, longitudinal pilot study","volume":"62","author":"Severance","year":"2017","journal-title":"Brain. Behav. Immun."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1145","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1464550","article-title":"Unlocking the secrets of trace amine-associated receptor 1 agonists: new horizon in neuropsychiatric treatment","volume":"15","author":"Shajan","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1150","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/07853890801923753","article-title":"Mitochondrial involvement in psychiatric disorders","volume":"40","author":"Shao","year":"2008","journal-title":"Ann. Med."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1155","author":"Sheba Medical Center"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neulet.2010.09.074","article-title":"No association between the KCNH1, KCNJ10 and KCNN3 genes and schizophrenia in the Han Chinese population","volume":"487","author":"Shen","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1165","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3390\/jpm13091395","article-title":"Associations of BDNF\/BDNF-AS SNPs with depression, schizophrenia, and bipolar disorder","volume":"13","author":"Shkundin","year":"2023","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1170","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3390\/genes13030457","article-title":"Genetic predisposition to schizophrenia and depressive disorder comorbidity","volume":"13","author":"Shnayder","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1175","doi-asserted-by":"crossref","first-page":"182","DOI":"10.12688\/wellcomeopenres.21302.1","article-title":"Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data","volume":"9","author":"Siafis","year":"2024","journal-title":"Wellcome Open Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1180","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1120532","article-title":"The adenosine hypothesis of schizophrenia into its third decade: From neurochemical imbalance to early life etiological risks","volume":"17","author":"Singer","year":"2023","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1185","series-title":"Current Antipsychotics","first-page":"187","article-title":"Antipsychotics in the treatment of bipolar disorder","author":"Singh","year":"2012"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1190","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1192\/bjp.2021.61","article-title":"Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis","volume":"220","author":"Siskind","year":"2022","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1195","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1176\/ajp.133.2.197","article-title":"The dopamine hypothesis of schizophrenia: focus on the dopamine receptor","volume":"133","author":"Snyder","year":"1976","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1205","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S1092852918001013","article-title":"Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate","volume":"23","author":"Stahl","year":"2018","journal-title":"CNS Spectr."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1210","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/biom12010108","article-title":"Early blockade of CB1 receptors ameliorates schizophrenia-like alterations in the neurodevelopmental MAM model of schizophrenia","volume":"12","author":"Stark","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1215","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.schres.2013.08.020","article-title":"Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo","volume":"150","author":"Stauffer","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1220","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3390\/molecules23082087","article-title":"Current concepts and treatments of schizophrenia","volume":"23","author":"St\u0119pnicki","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1225","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ajmg.b.20132","article-title":"Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiplex sample","volume":"127B","author":"Stone","year":"2004","journal-title":"Am. J. Med. Genet. Part B Neuropsychiatr. Genet. Off. Publ. Int. Soc. Psychiatr. Genet."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1230","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/341750","article-title":"Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia","volume":"71","author":"Straub","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1235","first-page":"341","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry Off. J. World Psychiatr. Assoc. WPA"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1240","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00702-022-02566-6","article-title":"Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized, placebo-controlled trial","volume":"130","author":"Strube","year":"2023","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1245","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1038\/s41598-019-41572-9","article-title":"Measurement of lactate levels in postmortem brain, iPSCs, and animal models of schizophrenia","volume":"9","author":"Sullivan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1250","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1007\/s12035-018-1390-4","article-title":"Connectivity analyses of bioenergetic changes in schizophrenia: identification of novel treatments","volume":"56","author":"Sullivan","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1255","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2217\/epi-2016-0106","article-title":"Understanding epigenetics of schizophrenia in the backdrop of its antipsychotic drug therapy","volume":"9","author":"Swathy","year":"2017","journal-title":"Epigenomics"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1260","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fpsyt.2020.00156","article-title":"The gut microbiome and schizophrenia: the current state of the field and clinical applications","volume":"11","author":"Szeligowski","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1265","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1186\/s12888-023-05292-9","article-title":"Association of DRD2, DRD4 and COMT genes variants and their gene-gene interactions with antipsychotic treatment response in patients with schizophrenia","volume":"23","author":"Taheri","year":"2023","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1270","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.schres.2013.02.033","article-title":"Reduction of cortical GABAergic inhibition correlates with working memory impairment in recent onset schizophrenia","volume":"146","author":"Takahashi","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1275","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2011.61","article-title":"Disease- and age-related changes in histone acetylation at gene promoters in psychiatric disorders","volume":"1","author":"Tang","year":"2011","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1280","first-page":"153","article-title":"Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders","volume":"86","author":"Teal","year":"2019","journal-title":"Adv. Pharmacol. San Diego Calif"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1285","doi-asserted-by":"crossref","first-page":"pyae066","DOI":"10.1093\/ijnp\/pyae066","article-title":"Therapeutic potential of D-amino acid oxidase inhibitors for cognitive impairment associated with schizophrenia: learnings from luvadaxistat","volume":"28","author":"Terry-Lorenzo","year":"2024","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1290","doi-asserted-by":"crossref","DOI":"10.4137\/BMI.S22007","article-title":"Immunomodulatory effects of probiotic supplementation in schizophrenia patients: a randomized, placebo-controlled trial","volume":"10","author":"Tomasik","year":"2015","journal-title":"Biomark. Insights"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1300","series-title":"Neuroinflammation and Schizophrenia, Current Topics in Behavioral Neurosciences","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/7854_2018_88","article-title":"Cytokines, oxidative stress and cellular markers of inflammation in schizophrenia","author":"Upthegrove","year":"2019"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192658","article-title":"The interaction between cannabis use and the Val158Met polymorphism of the COMT gene in psychosis: a transdiagnostic meta \u2013 analysis","volume":"13","author":"Vaessen","year":"2018","journal-title":"PLOS ONE"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1310","first-page":"492","article-title":"The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs","volume":"160","author":"van Rossum","year":"1966","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1315","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3390\/genes12121850","article-title":"Gene-environment interactions in schizophrenia: a literature review","volume":"12","author":"Wahbeh","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1320","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3892\/etm.2014.2014","article-title":"microRNAs as novel biomarkers of schizophrenia (review)","volume":"8","author":"Wang","year":"2014","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1325","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2024.111075","article-title":"Neuregulin-1 immunoreactivity in peripheral plasma is associated with rs6982890 polymorphism-mediated psychotic symptoms in schizophrenia","volume":"217","author":"Wang","year":"2024","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1330","doi-asserted-by":"crossref","first-page":"1365673","DOI":"10.3389\/fimmu.2024.1365673","article-title":"The microbiota-gut-brain-immune interface in the pathogenesis of neuroinflammatory diseases: a narrative review of the emerging literature","volume":"15","author":"Warren","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1335","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.euroneuro.2023.04.007","article-title":"A randomized controlled trial of add-on naproxen, simvastatin and their combination for the treatment of schizophrenia or schizoaffective disorder","volume":"73","author":"Weiser","year":"2023","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1340","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.110145","article-title":"Gut microbiota, kynurenine pathway and mental disorders - review","volume":"106","author":"Wi\u0119d\u0142ocha","year":"2021","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1345","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00005-012-0210-1","article-title":"Inflammation, cytokines and insulin resistance: a clinical perspective","volume":"61","author":"Wieser","year":"2013","journal-title":"Arch. Immunol. Ther. Exp. (Warsz.)"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1350","doi-asserted-by":"crossref","first-page":"396","DOI":"10.47102\/annals-acadmedsg.V38N5p396","article-title":"Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress","volume":"38","author":"Wood","year":"2009","journal-title":"Ann. Acad. Med. Singapore"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1355","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/bmj.2.4880.122","article-title":"Some neurophysiological aspects of serotonin","volume":"2","author":"Woolley","year":"1954","journal-title":"Br. Med. J."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1360","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.995956","article-title":"The emerging role of long non-coding RNAs in schizophrenia","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1365","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2174\/1570159X21666230817153631","article-title":"Stress, environment and early psychosis","volume":"22","author":"Xenaki","year":"2024","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1370","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.euroneuro.2016.11.012","article-title":"Adjunctive minocycline for schizophrenia: a meta-analysis of randomized controlled trials","volume":"27","author":"Xiang","year":"2017","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1375","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3390\/jpm11100987","article-title":"Lipid and energy metabolism of the gut microbiota is associated with the response to probiotic bifidobacterium breve strain for anxiety and depressive symptoms in schizophrenia","volume":"11","author":"Yamamura","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1380","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12888-023-05479-0","article-title":"Variations of plasma oxidative stress levels in male patients with chronic schizophrenia. Correlations with psychopathology and matrix metalloproteinase-9: a case-control study","volume":"24","author":"Yang","year":"2024","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1385","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2025.1681559","article-title":"Effects of gut microbiota interventions on patients with schizophrenia: a systematic review and meta-analysis","volume":"16","author":"Ye","year":"2025","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1390","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.neuropharm.2017.09.012","article-title":"Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia","volume":"136","author":"Yohn","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1395","doi-asserted-by":"crossref","first-page":"1421554","DOI":"10.3389\/fpsyt.2024.1421554","article-title":"The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia","volume":"15","author":"Yohn","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1400","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.schres.2022.02.033","article-title":"AMPA receptors in schizophrenia: a systematic review of postmortem studies on receptor subunit expression and binding","volume":"243","author":"Yonezawa","year":"2022","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1405","first-page":"4340","article-title":"Investigating aberrantly expressed microRNAs in peripheral blood mononuclear cells from patients with treatment-resistant schizophrenia using miRNA sequencing and integrated bioinformatics","volume":"22","author":"You","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1410","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107633","article-title":"IUPHAR review: drug repurposing in schizophrenia - an updated review of clinical trials","volume":"213","author":"Zaki","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1415","first-page":"1","article-title":"Glutamate modulators for treatment of schizophrenia","volume":"15\u201316","author":"Zhand","year":"2019","journal-title":"Pers. Med. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1420","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/schbul\/sbv116","article-title":"Association of a schizophrenia risk variant at the DRD2 locus with antipsychotic treatment response in first-episode psychosis","volume":"41","author":"Zhang","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2026.111749_bb1425","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41537-025-00684-0","article-title":"Resolving the heterogeneity of dopamine subsystems dysfunction in schizophrenia: a PET meta-analysis","volume":"11","author":"Zhao","year":"2025","journal-title":"Schizophrenia"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1430","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41537-024-00497-7","article-title":"Gut microbiome and schizophrenia: insights from two-sample Mendelian randomization","volume":"10","author":"Zhou","year":"2024","journal-title":"Schizophrenia"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1435","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41398-025-03449-6","article-title":"Multi-kingdom microbial changes and their associations with the clinical characteristics in schizophrenia patients","volume":"15","author":"Zhu","year":"2025","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111749_bb1440","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40263-023-01057-w","article-title":"Insulin resistance\/diabetes and schizophrenia: potential shared genetic factors and implications for better management of patients with schizophrenia","volume":"38","author":"Zhuo","year":"2024","journal-title":"CNS Drugs"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626001466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626001466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:40:58Z","timestamp":1785206458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584626001466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":271,"alternative-id":["S0278584626001466"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111749","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in schizophrenia research and treatment: exploring neurotransmitter imbalances, genetics, and innovative therapies","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111749","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111749"}}